Business Description
BioAtla Inc
NAICS : 541714
SIC : 2833
ISIN : US09077B1044
Share Class Description:
BCAB: Ordinary SharesTotal Employee Number:
41Compare
Compare
Traded in other countries / regions
BCAB.USA Index Membership
Russell 2000Russell 2000Russell 3000 IPO Date
2020-12-16Description
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.32 | |||||
Equity-to-Asset | -4.36 | |||||
Debt-to-Equity | -0.16 | |||||
Debt-to-EBITDA | -0.12 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -111.88 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 28.6 | |||||
3-Year EPS without NRI Growth Rate | 28.2 | |||||
3-Year FCF Growth Rate | 29.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 79.31 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.23 | |||||
9-Day RSI | 39.11 | |||||
14-Day RSI | 41.51 | |||||
3-1 Month Momentum % | -1.66 | |||||
6-1 Month Momentum % | -69.22 | |||||
12-1 Month Momentum % | -76.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.15 | |||||
Quick Ratio | 0.15 | |||||
Cash Ratio | 0.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 16 | |||||
Shareholder Yield % | -92.28 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -2549.95 | |||||
Net Margin % | -2530.85 | |||||
EBITDA Margin % | -2534.45 | |||||
FCF Margin % | -1859.15 | |||||
OCF Margin % | -1859.15 | |||||
ROA % | -244.01 | |||||
ROIC % | -634.28 | |||||
3-Year ROIIC % | 4268.79 | |||||
ROC (Joel Greenblatt) % | -1056.19 | |||||
ROCE % | -2424.6 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.97 | |||||
EV-to-EBIT | -0.19 | |||||
EV-to-EBITDA | -0.19 | |||||
EV-to-Revenue | 4.81 | |||||
EV-to-Forward-Revenue | 4.68 | |||||
EV-to-FCF | -0.26 | |||||
Earnings Yield (Greenblatt) % | -526.32 | |||||
FCF Yield % | -678.89 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BCAB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioAtla Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2 | ||
| EPS (TTM) ($) | -41.72 | ||
| Beta | 1.3488 | ||
| 3-Year Sharpe Ratio | -0.64 | ||
| 3-Year Sortino Ratio | -0.81 | ||
| Volatility % | 112.64 | ||
| 14-Day RSI | 41.51 | ||
| 14-Day ATR ($) | 0.325018 | ||
| 20-Day SMA ($) | 3.72 | ||
| 12-1 Month Momentum % | -76.94 | ||
| 52-Week Range ($) | 3.12 - 71.5 | ||
| Shares Outstanding (Mil) | 1.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioAtla Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioAtla Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 16:30 | In 105 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 104 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 7 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 6 days | ||
| General meeting for 2026 | 2026-06-16 08:00 | 3.62 (-9.27%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 4.37 (-0.68%) | ||
| 0.02:1 Stock Split | 2026-04-06 | 6.52 (-4.82%) | ||
| Annual report for 2025 | 2026-03-31 | 7.70 (-4.35%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 7.70 (-4.35%) | ||
| Third quarter earnings conference call for 2025 | 2025-11-13 16:30 | 34.39 (+1.49%) |
Show
Entries
BioAtla Inc Frequently Asked Questions
What is BioAtla Inc(BCAB)'s stock price today?
The current price of BCAB is $3.30. The 52 week high of BCAB is $71.50 and 52 week low is $3.12.
When is next earnings date of BioAtla Inc(BCAB)?
The next earnings date of BioAtla Inc(BCAB) is 2026-08-07 Est..
Does BioAtla Inc(BCAB) pay dividends? If so, how much?
BioAtla Inc(BCAB) does not pay dividend.
Guru Commentaries on NAS:BCAB
No articles.
Press Release
Articles on BioAtla Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers